Recipharm Invests In Its Single Dose Nasal Platform Capabilities

November 30, 2022

Recipharm, a global contract development and manufacturing organisation (CDMO), has announced that it is expanding its capabilities for its proprietary Unidose Xtra (single dose) nasal delivery platform. 

Offering advantages over standard systemic delivery systems, Recipharm has seen interest in intranasal drug delivery in pharmaceutical R&D increase significantly over the last 10 years. The potential benefits of nasal delivery include offering a more favourable patient experience, with targeted delivery resulting in a faster response to the medication. 

Recipharm has already invested in several of its sites in the UK and US to expand its capabilities for the Unidose Xtra delivery platform and the following services are now available: 

• Development of Unidose Xtra prototypes 

• Filling and assembly capabilities to support pre-clinical evaluations

• System performance testing with regards to spray characteristics 

The following services using performance-ready components will be offered: 

• Full method development 

• Formulation and Container Closure System (CCS) screening/characterisation

• GMP material manufacturing and supply 

• Development stability testing 

A feasibility study package will also be available. Furthermore, Recipharm’s new GMP suite is being built in North Carolina to support clinical manufacturing. 

Joe Neale, Head of Innovation, Development and Programme Management at Recipharm said: “Our customers and therefore patients can benefit from  Recipharm’s superior product, and we are proud to be creating a benchmark for ‘real world nasal drug delivery performance’. Our ability to offer drug formulation-specific tailoring provides a competitive advantage.”


Recipharm Advanced Delivery Systems is now Bespak, a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery devices and drug-device combination products.

For further information and interview opportunities with Bespak, please contact:

Sarah Guinane at Notch Communications

[email protected]

About Bespak

Bespak is a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery devices and drug-device combination products. Bespak develops and manufactures finished pharmaceutical products, as well as being a leading global supplier of drug delivery devices and componentry to the pharmaceutical industry. With a long history in the development and commercial supply of pressurised Metered Dose Inhalers (pMDIs), Bespak supplies a major proportion of the world’s pMDI dosing valves and actuators, and also specialises in the industrialisation and high-volume manufacture of complex dry powder inhaler (DPI) devices.

Headquartered in Holmes Chapel, UK, the company’s service offering spans early-stage feasibility, analytical services and product development, from pilot-scale, through to clinical supply and commercial-scale drug product fill-finish, device and component manufacturing.

More information: www.bespak.com

You may also like